APTN — ADAPTIN BIO, INC. ☆

Adaptin Bio, Inc., a biotechnology company, develops drug delivery technologies to deliver drugs and other compounds directly to target destinations within the body in the United States. It provides Brain Bispecific T-cell Engager platform, a bispecific antibody technology to target and treat intracerebral malignancies, such as gliomas. It develops APTN-101, a proprietary epidermal growth factor receptor variant III to eliminate malignant glioma tumors in a range of aggressive preclinical tumor models. It caters to patients with oncology, CNS, autoimmune, and cardiovascular conditions, as well as healthcare professionals, researchers, and biopharma partners. The company was founded in 2021 and is based in Charlotte, North Carolina.